Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

SUPPLEMENTARY APPENDIX

RECOVERY Collaborative Group

Contents

Details of the RECOVERY Collaborative Group ................................................................. 2
Supplementary Methods .................................................................................................. 20
  Study organization ......................................................................................................... 20
  Protocol changes ........................................................................................................... 20
  Ascertainment and classification of study outcomes .................................................... 21
  Interim analyses: role of the Data Monitoring Committee ............................................. 21
Supplementary Tables .................................................................................................... 22
  Table S1: Treatments given, by randomized allocation .................................................. 23
  Table S2: Impact of adjusting for the 1.1-year age imbalance between randomised arms on the estimated effect of allocation to dexamethasone on 28-day mortality, both in all randomized patients and in subgroups defined by respiratory support received at randomization ........................................................................................................... 24
Supplementary Figures .................................................................................................. 25
  Figure S1: Trial profile - Flow of participants through the RECOVERY trial .................. 26
  Figure S2: Effect of allocation to dexamethasone on 28–day mortality by other pre-specified baseline characteristics .......................................................................................... 27
  Figure S3: Effect of allocation to dexamethasone on: a) time to discharge; and b) mechanical ventilation or death, by respiratory support received at randomization .... 28
Details of the RECOVERY Collaborative Group

Writing Committee


*, † equal contribution

Steering Committee

Co-Chief Investigators P Horby, MJ Landray; Clinical Trial Unit Leads R Haynes, E Juszczak; Members JK Baillie, L Chappell, SN Faust, T Jaki, K Jeffery, WS Lim, M Mafham, A Montgomery, K Rowan.

Data Monitoring Committee


RECOVERY Trial Central Coordinating Office

Co-Chief Investigators P Horby, MJ Landray; Clinical Trial Unit Leads R Haynes, E Juszczak; Trial management L Fletcher (coordinator), J Barton, A Basoglu, R Brown, W Brudlow, S Howard, K Taylor; Programming and validation B Goodenough, G Cui, A King, M Lay, D Murray, W Stevens, K Wallendszuz, R Welsh; Data linkage C Crichton, J Davies, R Goldacre, F Knight, J Latham-Mollart, M Mafham, M Nunn, H Salih, J Welch; Clinical support G Pessoa-Amorim; Quality assurance C Knott, J Thomas, R Ushe; Statistics J Bell, J Emberson, E Juszczak, L Linsell, N Staplin; Communications G Bagley, S Cameron, S Chamberlain, B Farrell, H Freeman, A Kennedy, A Whitehouse

National Institute for Health Research Clinical Research Network

Paediatric working group

Obstetric working group
L Chappell (coordinator), M Knight, S Pavord, C Williamson.

Clinical support
NHS Lothian Out of Hours support line team M Odam (coordinator), P Black, B Gallagher, L Macllnnes, R O’Brien, K Priestley, A Sauderson; Clinical Trial Service Unit Out of Hours clinical support L Bowman, F Chen, R Clarke, M Goonasekara, R Haynes, W Herrington, P Judge, M Matham, S Ng, D Preiss, C Reith, E Sammons, D Zhu.

Health records

Drug supply

Local Clinical Centre RECOVERY trial staff
(listed in descending order of the number of patients randomised per site)


Nottingham University Hospitals NHS Trust WS Lim (PI), M Ali, D Ashton, G Babington, D Batra, L Bendall, A Buck, G Bugg, J Butler, J Cantliff, P Davies, A Fatemi, F Fatemi, M Fatemi, L Fleming, L Hodgen, L Howard, C Hutchinson, B Jackson, C Khurana, M Langley,


North Tees and Hartlepool NHS Foundation Trust B Prudon (PI), N Aung (Co-PI), R Srinivasan (Co-PI), S Wild (Co-PI), C Adams, D Barker, B Campbell, V Collins, J Deane, S Gowans, L Poole, S Purvis, J Quigley, A Ramshaw, L Shepherd, J Skelton, R Taylor, M Walker, M Weetman, B Wetherall.


Oxford University Hospitals NHS Foundation Trust  

Luton and Dunstable University Hospitals NHS Foundation Trust  

Epsom and St Helier University Hospitals NHS Trust  

Buckinghamshire Healthcare NHS Trust  

Frimley Health NHS Foundation Trust  

NHS Lothian: Royal Infirmary of Edinburgh  

Wrightington, Wigan and Leigh NHS Foundation Trust  

Barts Health NHS Trust  


North Middlesex University Hospital NHS Trust J Moreno-Cuesta (PI), S Rokadiya (Co-PI), A Govind, A Haldeos, K Leigh-Ellis, V Rachel, C van Someren, R Vincent.


University Hospitals Of Derby and Burton NHS Foundation Trust  T Bewick (PI), P Daniel (Co-PI), U Nanda (Co-PI), G Bell, C Downes, K English, A Fletcher, J Hampson, M Hayman, S Ohja, J Radford, K Riches, G Robinson, A Sathyanarayanan, F Scothern, L Wilcox, L Wright.


University Hospitals Coventry and Warwickshire NHS Trust  K Patel (PI), C Imray (Co-PI), N Aldridge, A Campbell, G Evans, E French, R Grenfell, S Hewins, D Hewitt, J Jones, R Kumar, E Mshengu, S Quenby, K Read, P Satodia, M Truslove.


Southend University Hospital NHS Foundation Trust  G Koduri (PI), S Gokaraju (Co-PI), F Hayes (Co-PI), WW Vijayaraghavan Nalini (Co-PI), V Gupta, P Harman.

Sherwood Forest Hospitals NHS Foundation Trust  M Roberts (PI), K Amsha (Co-I), G Cox (Co-I), N Downer (Co-I), D Hodgson (Co-I), J Hutchinson (Co-I), S Kalsoom (Co-I), A Molyneux (Co-I), Z Noor (Co-I), L Allsop, P Buckley, L Dunn, M Gill, C Heely, M Holmes, C Moulds, D Nash, J Rajeswary, S Shelton, S Smith, I Wynter, M Yannay.


Imperial College Healthcare NHS Trust  G Cooke (PI), Z Al-Saadi, A Daunt, L Evison, C Gale, M Gibani, B Jones, J Labao, N Madeja, H McLachlan, A Perry, R Thomas, E Whittaker, C Wignall, P Wilding, L Young, C Yu.

The Dudley Group NHS Foundation Trust  H Ashby (PI), P Amy, S Ashman-Flavell, S de Silva, J Dean, N Fisher, E Forsey, J Frost, S Jenkins, D Kaur, A Lubina Solomon, S...
Dexamethasone for COVID-19 – Preliminary Report

Mahadevan-Bava, T Mahendiran, M O’Toole, S Pinches, D Rattehalli, U Sinha, M Subramanian, J Vamvakopoulos, S Waidyanatha.


St George’s University Hospitals NHS Foundation Trust T Bicanic (PI), T Harrison (Co-PI), A Adebiyi, T Samakomva, St Georges COVID 19 Research Team.

James Paget University Hospitals NHS Foundation Trust J Patrick (PI), B Burton (Co-I), J Chapman, V Choudhary, C Hacon, K Mackintosh, H Sutherland, M Whelband, E Wilhelmsen.

West Suffolk NHS Foundation Trust M Moody (PI), S Barkha (Sub-PI), S Bhagat, H Cockerill, J Godden, J Kellett, T Murray, P Oats, A Saraswatula, A Williams, L Wood.


South Tyneside and Sunderland NHS Foundation Trust E Fuller (PI), A MacNair (Co-PI), M Rangar (Co-PI), N Mullen PI (Paediatrics), C Brown, A Burns, C Caroline, R Davidson, M Dickson, B Duncan, N Elkaram, I Emmerson, L Fairlie, M Hashimm, J Henderson, K Hinshaw, J Holden, S Laybourne, P Madgwick, K Martin, M McKee, J Moore, P Murphy, R Shahrul, A Smith, L Smith, M Smith, B Stidolph, L Terry, A Trotter, F Wakinshaw, M Walton.


United Lincolnshire Hospitals NHS Trust M Chablani (PI), R Barber (Co-PI), S Archer, R Barber, S Butler, A Chingale, C Flood, O Francis, A Kirkby, R Mishra, K Netherton, L Osborne, A Reddy, A Sloan.


Kingston Hospital NHS Foundation Trust S Mahendran (PI), A Joseph (Co-PI), A Baggaley, G Bambridge, F Bazari, P Beak, A Conroy, J Crooks, B Crowe, D Donnelly, A Edwards, S El-Sayeh, A Febe, J Fox, R Gisby, J Haugh, R Herdan-Grant, D Jajbhay, O

Liverpool University Hospitals NHS Foundation Trust S Todd (PI), I Welters (Co-PI), D Wootton (Co-PI), A Al Balushi, D Barr, J Byrne, D Coey, T Cross, J Cruise, K Haigh, C Hall, M Harrison, S Hope, K Hunter, S Iyer, A Jackson, J Keogan, J Lewis, P Lopez, C Lowe, M Middleton, M Nugent, L Pauls, I Quayle, S Raghunath, M Riley, J Sedano, D Shaw, S Stevenson, A Stockdale, R Tangney, V Waugh, K Williams.

Bedford Hospital NHS Trust E Thomas (PI), D Bagmane (Co-PI), B Jallow (Co-PI), I Nadeem (Co-PI), M Negmeldin (Co-PI), A Vaidya (Co-PI), A Amjad, A Anthony-Pillai, I Armata, R Arora, R Bhanot, D Callum, P Chrysostomou, F De Santana Miranda, S Farnworth, N Fatimah, L Grosu, A Haddad, M Hikmat, UF Khatana, I Koopmans, E Lister, R Lorusso, N Nathaniel, CS Ong, K Pandya, M Penacerrada, S Rahama, L Salih, W Tan, S Trussell, J Valentine, R Wulandari.


NHS Greater Glasgow and Clyde: Queen Elizabeth University Hospital M Sim (Co-PI), K Blythe (Co-PI), L Jawaweera (Co-PI), L Pollock (Co-PI), S Wishart (Co-PI), M McGortick (Sub-I), J Rollo (Sub-I), N Baxter, J Ferguson, K Ferguson, S Henderson, S Kennedy-Hay, A Kidd, MA Ledingham, M Lowe, R McDougall, M McCadden, N McGlinchey, L McKay, B McLaren, C McParland, J McTaggart, J Millar, L Rooney, H Stubbs, M Wilson.


Brighton and Sussex University Hospitals NHS Trust M Llewelyn (PI), H Brown, E Barbon, G Bassett, L Bennett, A Bexley, Z Cipinova, J Gaylard, Z He, C Laycock, D Mullan, C Richardson, V Sellick, D Skinner, M Smith.

NHS Lothian: Western General Hospital O Koch (PI), A Abu-Arafeh, E Allen, C Balmforth, A Barnett-Vanes, R Baruah, S Blackley, S Clifford, A Clarke, M Curtin, M Evans, C Ferguson, S Ferguson, N Fethers, N Freeman, E Godden, R Harrison, B Hasting, S Htwe, AJW Kwek, O Lloyd, C Mackintosh, A MacRaild, W Mahmood, E Mahony, J McCrae,
Moatt, S Morris, C Mutch, K Nunn, M Perry, J Rhodes, N Rodgers, A Shepherd, R Sutherland, A Tasiou, A Tufail, D Waters, T Wilkinson, R Woodfield, J Wubetu.

Southern HSC Trust  R Convery (PI), J Brannigan, D Cosgrove, C McCullough, D McFarland, R McNulty, S Sands, O Thompson.


Shrewsbury and Telford Hospital NHS Trust  J Moon (PI), N Biswas, A Bowes, H Button, M Carnhan, S Deshpande, C Fenton, M Ibrahim, J Jones, H Millward, M Rees, N Schunke, J Stickley, M Tadros, H Tivenan.

Swansea Bay University Local Health Board  B Healy (PI), S Bareford, I Blyth, A Bone, E Brinkworth, R Chudleigh, Y Ellis, S Georges, S Green, R Harford, J Harris, A Holborow, C Johnston, P Jones, M Krishnan, N Leopold, F Morris, A Mughal, E Pratt, T Rees, G Saleeb, J Watts, M Williams.

St Helens and Knowsley Teaching Hospitals NHS Trust  G Barton (PI), S Dealing, R Garr, S Greer, N Hornby, S Mayor, A McCairn, S Rao.


Dorset County Hospital NHS Foundation Trust  J Chambers (PI), J Birch, L Bough, J Graves, S Horton, R Thomas, W Verling, S Williams, P Williams, B Winter-Goodwin, S Wiseman, D Wixted.

The Queen Elizabeth Hospital, King’s Lynn, NHS Foundation Trust  M Blunt (PI), J Ali, K Beaumont, K Bishop, H Bloxham, P Chan, Z Coton, H Curgenven, M Elsadany, T Fuller, M Iqbal, M Israa, S Jeddri, SA Kamar, EET Lim, E Nadar, K Naguleswaran, O Poluyi, G Rewitzky, S Ruff, A Velusamy.


The Royal Wolverhampton NHS Trust S Gopal (PI), R Barlow, CH Cheong, D Churchill, K Davies, M Green, N Harris, A Kumar, S Metherell, S Milgate, L Radford, J Rogers, A Smallwood.


Mid Essex Hospital Services NHS Trust A Hughes (PI), J Radhakrishnan (Co-PI), T Camburn, C Catley, E Dawson, C Fox, N Fox, H Gerrish, S Gibson, H Guth, F McNeela, A Rao, S Reid, B Singizi, S Smolen, S Williams, L Willsher, J Wootton.


East Lancashire Hospitals NHS Trust  S Chukkambotla (PI), S Duberley, W Goddard, K Marsden.

Milton Keynes University Hospital NHS Foundation Trust  R Stewart (PI), S Bowman (Co-PI), A Chakraborty (Co-PI), L How (Co-PI), D Mital (Co-PI), L Anguavaa, J Bae, G Bega, S Bosompem, E Clare, A Dooley, S Fox, J Mead, S Mehdi, L Mew, L Moran, E Mwaura, M Nathvani, A Oakley, A Rose, A Sanaullah, D Scaletta, S Shah, L Siamia, J Smith, O Spring, S Velankar, F Williams, L Wren, F Wright.


South Eastern HSC Trust  D Alderdice (PI), J Courtney (Co-I), J Elder (Co-I), D Hart (Co-I), K Henry (Co-I), R Hewitt (Co-I), A Kerr (Co-I), J McKeever (Co-I), C O’Gorman (Co-I), S Rowan (Co-I), T Trinick (Co-I), B Valecka (Co-I), P Yew (Co-I), V Adelli, J Baker, A Campbell, J Foreman, P Gillen, S Graham, S Hagan, L Hammond, J MacIntyre, A Smith, G Young.


George Eliot Hospital NHS Trust  S George (PI), K Ellis, V Gulia, J Gunn, E Hoverd, T Kannan, R Musanhu, N Navaneetham, D Suter.

NHS Lanarkshire: University Hospital Monklands  M Patel (PI), C McGoldrick (Co-PI), C Beith, L Ferguson, L Glass, P Grant, S MacFadyen, A McAlpine, M McLaughlin, S Rundell, C Sykes, M Taylor, B Welsh.


NHS Lanarkshire: University Hospital Wishaw  M Patel (PI), K Black, R Boyle, S Clements, J Fleming, L Glass, L Hamilton, E Jarvie, C MacDonald, D Vigni, B Welsh, P Wu.

Poole Hospital NHS Foundation Trust  H Reschreiter (PI), S August, C Barclay, S Blunden, S Bokhandi, J Camsooksai, S Chessell, C Colvin, J Dube, S Grigsby, C Humphrey, S Jenkins, S Patch, A Shah, M Tighe, L Vinayakarao, B Wadams, E Woodward, M Woolcock.
Gateshead Health NHS Foundation Trust R Alcock (PI), M Armstrong, J Barbour, A Dale, V Deshpande, I Hashmi, E Johns, D Mansour, B McClelland, C McDonald, C Moller-Christensen, R Petch, R Sharma, L Southern, G Stiller.


Wye Valley NHS Trust I DuRand (PI), P Ryan (Deputy PI), J Al-Fori, J Birch, N Bray, A Carrasco, M Cohn, E Collins, S Cooper, A Davies, M Evans, K Hammerton, S Meyrick, B Mwale, L Myslivecek, C Seagrave, F Suliman, S Turner, J Woolley.

Worcestershire Acute Hospitals NHS Trust C Hooper (PI), K Austin, T Dawson, A Durie, C Hillman-Cooper, M Ling, J Tyler, P Watson, H Wood.


Cwm Taf Morgannwg University LHB C Lynch (PI), B Deacon, S Eccles, B Gibson, C Lai, L Margarit, DS Nair, S Owen, L Roche, S Sathe.

Betsi Cadwaladr LHB: Glan Clwyd Hospital D Menzies (PI), K Darlington, F Davies, G Davis, I Davis, J Lewis, S Rees, N Sengupta, H Williams.

University College London Hospitals NHS Foundation Trust H Esmail (PI), RS Heyderman (Co-PI), DAJ Moore (Co-PI), F Beynon, PN Bodalia, XHS Chan, CY Chung, D Crilly, J Gahir, L Germain, J Glanville, E Kilich, N Lack, N Platt, I Skorupinska, M Skorupinska, J Spillane, N Z Fard.


Homerton University Hospital NHS Foundation Trust K Woods (PI), A Claxton (Co-PI), Y Akinfenwa, N Aladangady, H Bouattia, R Brady, R Corser, H Furreed, C Holbrook, S Jain, J Kaur, C Mitchell-Inwang, R Mullett, T Tanqueray, E Timlick,


Guy’s and St Thomas’ NHS Foundation Trust H Winslow (PI), L Brace, K Brooks, L Chappell, M Flanagan, J Kenny, G Nishku, C Singh, E Wayman, C Williamson, H Winslow, C Yearwood Martin.


Barnsley Hospital NHS Foundation Trust K Inweregbu (PI), M Cunningham, A Daniels, L Harrison, S Hope, A Nicholson.

West Hertfordshire Hospitals NHS Trust V Page (PI), R Vancheswaran (Co-PI), L Norris, T Varghese, X Zhao.


NHS Lothian: St John's Hospital S Lynch (PI), S Begg, M Colmar, C Cheyne, R Frake, A Gatenby, C Geddie, F Guarino, C Kuronen-Stewart, A MacRaild, M Mancuso-Marcello, M Odam, OK Otite, L Primrose, A Saunderson, A Williams.


Isle Of Wight NHS Trust  M Pugh (PI), A Brown, S Grevatt, E Jenkins, S Knight, E Nicol, J Wilkins.


Harrogate and District NHS Foundation Trust  A Kant (PI), C Taylor (Co-PI), A Amin, A Daly, SJ Foxton, E Lau, C Morgan, M Tripouki, L Wills.

South Warwickshire NHS Foundation Trust  S Tso (PI), P Parsons (Co-PI), S Bird, C Bannon, R Browne, B Campbell, S Dharwai, G Kakoullis, F Mackie, C O’Brien, K Webb.

Northern HSC Trust  P Minnis (PI), J Burns, L Davidson, A Fryatt, J Gallagher, C McGoldrick, M McMaster.

Hywel Dda LHB: Prince Philip Hospital  S Ghosh (PI), S Coetzee, K Davies, L O’Brien, Z Omar, CV Williams.

NHS Lanarkshire: University Hospital Hairmyres  M Patel (PI), F Burton (Co-PI), D Bell, R Boyle, D Cairney, K Douglas, L Glass, E Lee, L Lennon, B Welsh.

The Royal Marsden NHS Foundation Trust  K Tatham (PI), P Angelini, E Bancroft, E Black, A Dela Rosa, E Durie, I Leslie, S Shepherd, S Wong.


Royal Brompton & Harefield NHS Foundation Trust  A Shah (PI), A Reed (Co-PI), A Aramburo, R Mordi, C Prendergast, P Rogers, N Soussi, J Wallen.

Western HSC Trust  M Kelly (PI), D Concannon, D McClintock, V Mortland, N Smyth.
NHS Greater Glasgow and Clyde: Inverclyde Royal Hospital  M Azharuddin (PI), H Papaconstantinou (Co-PI), D Cartwright, T McClay, E Murray, O Olukoya.


The Walton Centre NHS Foundation Trust R Davies (PI), H Arndt, E Hetherington.

Hywel Dda LHB: Withybush Hospital J Green (PI), R Hughes, C Macphee, H Thomas.

Alder Hey Children's NHS Foundation Trust D Hawcutt (PI), D Afolabi, K Allison, S McWilliam, L O'Malley, L Rad, N Rogers, P Sanderson, G Seddon, J Whitbread.

Birmingham Women's and Children's NHS Foundation Trust K Morris (PI), J Groves, K Hong, D Jyothish, S Sultan.

Velindre NHS Trust J Powell (PI), R Adams (Co-PI), A Jackson.

NHS Western Isles G Stanczuk (PI), I Garcia Deniz, S Klaczek, M Murdoch.


NHS Golden Jubilee National Hospital B Shelley (PI), V Irvine, F Thompson.

Liverpool Women's NHS Foundation Trust R McFarland (PI), P Corlett, C Cunningham, S Holt, J McKenzie, C Morgan, M Turner.

Dragon's Heart Hospital J Coulson (PI), B Moore.
Supplementary Methods

Study organization
The RECOVERY trial is an investigator-initiated, individually randomized, open-label, controlled trial to evaluate the efficacy and safety of a range of putative treatments in patients hospitalized with COVID-19. The protocol is available at NEJM.org. The trial was conducted at 176 National Health Service (NHS) hospital organizations in the United Kingdom. The trial was coordinated by a team drawn from the Clinical Trial Service Unit and the National Perinatal Epidemiology Clinical Trials Unit within the Nuffield Department of Population Health at University of Oxford, the trial sponsor. Support for local site activities was provided by the National Institute for Health Research Clinical Research Network.

Treatment supply to local sites was supported by National Health Service (NHS) England and Public Health England. Access to relevant routine health care and registry data was supported by NHS DigiTrials, the Intensive Care National Audit and Research Centre, Public Health Scotland, National Records Service of Scotland, and the Secure Anonymised Information Linkage (SAIL) at University of Swansea.

Protocol changes
RECOVERY is a randomized trial among patients hospitalized for COVID-19. All eligible patients receive usual standard of care in the participating hospital and are randomly allocated between no additional treatment and one of several active treatment arms. Over time, additional treatment arms have been added (see Table). In version 4.0 of the protocol, a second randomization was introduced for those trial participants with hypoxia (oxygen saturation <92% on air or receiving oxygen) and inflammation (C-reactive protein ≥75 mg/dL), comparing the addition of tocilizumab vs. control on top of the treatment assigned in the first randomization. In version 6.0, a factorial design was introduced to the first randomization such that participants were also randomized to convalescent plasma vs. no additional treatment. As outlined in the protocol, if one or more of the active treatments was not available at the hospital or is believed, by the attending clinician, to be contraindicated (or definitely indicated) for the specific patient, then random allocation was between the remaining treatment arms.

The original and final protocol are included in the supplementary material to this publication, together with summaries of the changes made.

Table. Protocol changes to treatment comparisons

<table>
<thead>
<tr>
<th>Protocol version</th>
<th>Date</th>
<th>Randomization</th>
<th>Treatment arms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>13-Mar-2020</td>
<td>Main (part A)</td>
<td>No additional treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lopinavir-ritonavir</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low-dose corticosteroid</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nebulised Interferon-ß-1a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(never activated)</td>
</tr>
<tr>
<td>2.0</td>
<td>23-Mar-2020</td>
<td>Main (part A)</td>
<td>No additional treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lopinavir-ritonavir</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low-dose corticosteroid</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hydroxychloroquine</td>
</tr>
<tr>
<td>3.0</td>
<td>07-Apr-2020</td>
<td>Main (part A)</td>
<td>No additional treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lopinavir-ritonavir</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low-dose corticosteroid</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hydroxychloroquine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Azithromycin</td>
</tr>
<tr>
<td>4.0</td>
<td>14-Apr-2020</td>
<td>Main (part A)</td>
<td>No additional treatment Lopinavir-ritonavir Low-dose corticosteroid Hydroxychloroquine Azithromycin</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No additional treatment Tocilizumab</td>
</tr>
<tr>
<td>5.0</td>
<td>24-Apr-2020</td>
<td>-</td>
<td>(no change – extension to children &lt;18 years old)</td>
</tr>
<tr>
<td>6.0</td>
<td>14-May-2020</td>
<td>Main (part A)</td>
<td>No additional treatment Lopinavir-ritonavir Low-dose corticosteroid&lt;sup&gt;b&lt;/sup&gt; Hydroxychloroquine&lt;sup&gt;c&lt;/sup&gt; Azithromycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Main (part B factorial)</td>
<td>No additional treatment Convalescent plasma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No additional treatment Tocilizumab</td>
</tr>
</tbody>
</table>

<sup>a</sup> for patients with (a) oxygen saturation <92% on air or requiring oxygen or children with significant systemic disease with persistent pyrexia; and (b) C-reactive protein ≥75 md/dL)

<sup>b</sup> enrolment ceased 8 June 2020 as more than 2,000 patients had been recruited to the active arm

<sup>c</sup> enrolment ceased 5 June 2020 when the Data Monitoring Committee advised that the Chief Investigators review the unblinded data.

**Ascertainment and classification of study outcomes**

Information on baseline characteristics and study outcomes was collected through a combination of electronic case report forms completed by members of the local research team at each participating hospital and linkage to National Health Service, clinical audit, and other relevant health records. Full details are provided in the RECOVERY Definition and Derivation of Baseline Characteristics and Outcomes Document which was published online ([www.recoverytrial.net](http://www.recoverytrial.net)) on 9 June 2020.

**Interim analyses: role of the Data Monitoring Committee**

The independent Data Monitoring Committee reviews unblinded analyses of the study data and any other information considered relevant at intervals of around 2 weeks. The committee is charged with determining if, in their view, the randomized comparisons in the study provide evidence on mortality that is strong enough (with a range of uncertainty around the results that was narrow enough) to affect national and global treatment strategies. In such a circumstance, the Committee would inform the Steering Committee who would make the results available to the public and amend the trial arms accordingly. Unless that happened, the Steering Committee, investigators, and all others involved in the trial would remain blind to the interim results until 28 days after the last patient had been randomized to a particular intervention arm. Further details about the role and membership of the independent Data Monitoring Committee are provided in the protocol.
Supplementary Tables
Table S1: Treatments given, by randomized allocation

<table>
<thead>
<tr>
<th>Treatment allocation</th>
<th>Dexamethasone (n=2104)</th>
<th>Usual care (n=4321)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up forms received</td>
<td>1940</td>
<td>3973</td>
</tr>
<tr>
<td>Treatments given</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>1842 (95%)</td>
<td>285 (7%)</td>
</tr>
<tr>
<td>Lopinavir-Ritonavir</td>
<td>2 (0%)</td>
<td>5 (0%)</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>16 (1%)</td>
<td>20 (1%)</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>449 (23%)</td>
<td>970 (24%)</td>
</tr>
<tr>
<td>Tocilizumab or sarilumab</td>
<td>28 (1%)</td>
<td>99 (2%)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>17 (1%)</td>
<td>29 (1%)</td>
</tr>
</tbody>
</table>

Percentages are of those with a completed follow-up form. Among patients allocated dexamethasone, it was taken for a median of 6 days [IQR 3-10 days].
Table S2: Impact of adjusting for the 1.1-year age imbalance between randomised arms on the estimated effect of allocation to dexamethasone on 28-day mortality, both in all randomized patients and in subgroups defined by respiratory support received at randomization

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Treatment allocation</th>
<th>Age-adjusted Cox regression*</th>
<th>Unadjusted Cox regression†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dexamethasone (n=2104)</td>
<td>Usual care (n=4321)</td>
<td>RR (95% CI)</td>
</tr>
<tr>
<td>No oxygen received</td>
<td>85/501 (17.0%)</td>
<td>137/1034 (13.2%)</td>
<td>1.22 (0.93-1.61)</td>
</tr>
<tr>
<td>Oxygen only</td>
<td>275/1279 (21.5%)</td>
<td>650/2604 (25.0%)</td>
<td>0.80 (0.70-0.92)</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>94/324 (29.0%)</td>
<td>278/683 (40.7%)</td>
<td>0.65 (0.51-0.82)</td>
</tr>
<tr>
<td>All participants</td>
<td>454/2104 (21.6%)</td>
<td>1065/4321 (24.6%)</td>
<td>0.83 (0.74-0.92)</td>
</tr>
</tbody>
</table>

RR=rate ratio, CI=confidence interval. * Main analysis shown in Figures 1 and 2, in which the 28-day mortality rate ratio is estimated by the hazard ratio from a Cox regression analysis adjusted for age in three categories (<70 years, 70-79 years, and 80 years or older). † This analysis is shown to illustrate the impact on the estimated RRs (and their confidence intervals and associated p-values) of failing to adjust for the 1.1-year age imbalance between the randomised groups. Note: in the RECOVERY trial press release of 16 June 2020, effects in subgroups of level of respiratory support received were shown with 99% CIs, not 95% CIs as inadvertently stated. The age-adjusted rate ratio and 99% confidence intervals remain unchanged in this analysis: no oxygen required, RR 1.22 (99% CI 0.86-1.75); oxygen only, RR 0.80 (99% CI 0.67-0.96); invasive mechanical ventilation, RR 0.65 (99% CI 0.48-0.88). The unadjusted Cox regression RRs (and their 95% CIs and associated p-values) are virtually identical to the values obtained when using the 'one-step' method to estimate the average mortality rate ratio from the log-rank 'observed minus expected' statistic and its variance.
Supplementary Figures
Figure S1: Trial profile - Flow of participants through the RECOVERY trial

Total randomized
n = 6425

Allocated to Dexamethasone
n = 2104
Received dexamethasone
n = 1842/1940* (95%)

Consent withdrawn
n = 2 (0.1%)

Proceeded to second randomization†
 n = 92 (4.4%)

Included in 28 day ITT analysis
n = 2104 (100%)

Allocated to Usual care alone
n = 4321
Received dexamethasone
n = 285/3973* (7%)

Consent withdrawn
n = 7 (0.2%)

Proceeded to second randomization†
 n = 275 (6.4%)

Included in 28 day ITT analysis
n = 4321 (100%)

ITT – intention to treat
* 1940/2104 (92.1%) and 3973/4321 (91.9%) patients have a completed follow-up form at time of analysis.
† Randomization to Tocilizumab vs. No additional treatment in accordance with protocol version 4.0 or later. In addition, 14 patients were additionally randomized to convalescent plasma vs control (5 [0.2%] patients allocated to dexamethasone arm vs 9 [0.2%] patients allocated to usual care) in accordance with protocol V6.0.
Figure S2: Effect of allocation to dexamethasone on 28–day mortality by other pre−specified baseline characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Dexamethasone</th>
<th>Usual care</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years ($\chi^2 = 4.87; p=0.03$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;70</td>
<td>124/1142 (10.9%)</td>
<td>413/2506 (16.5%)</td>
<td>0.64 (0.52–0.78)</td>
</tr>
<tr>
<td>≥70 &lt;80</td>
<td>146/467 (31.3%)</td>
<td>262/860 (30.5%)</td>
<td>1.01 (0.82–1.23)</td>
</tr>
<tr>
<td>≥80</td>
<td>184/495 (37.2%)</td>
<td>390/955 (40.8%)</td>
<td>0.88 (0.74–1.05)</td>
</tr>
<tr>
<td>Sex ($\chi^2 = 1.13; p=0.29$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>312/1338 (23.3%)</td>
<td>754/2750 (27.4%)</td>
<td>0.79 (0.70–0.91)</td>
</tr>
<tr>
<td>Women</td>
<td>142/766 (18.5%)</td>
<td>311/1571 (19.8%)</td>
<td>0.90 (0.74–1.10)</td>
</tr>
<tr>
<td>Days since symptom onset ($\chi^2 = 12.26; p&lt;0.001$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤7</td>
<td>252/916 (27.5%)</td>
<td>478/1801 (26.5%)</td>
<td>1.01 (0.87–1.17)</td>
</tr>
<tr>
<td>&gt;7</td>
<td>201/1184 (17.0%)</td>
<td>581/2507 (23.2%)</td>
<td>0.68 (0.58–0.80)</td>
</tr>
<tr>
<td>Baseline risk ($\chi^2 = 0.22; p=0.64$)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30%</td>
<td>137/1255 (10.9%)</td>
<td>361/2680 (13.5%)</td>
<td>0.80 (0.66–0.98)</td>
</tr>
<tr>
<td>≥30% &lt;45%</td>
<td>157/500 (31.4%)</td>
<td>340/926 (36.7%)</td>
<td>0.81 (0.67–0.98)</td>
</tr>
<tr>
<td>≥45%</td>
<td>160/349 (45.8%)</td>
<td>364/715 (50.9%)</td>
<td>0.85 (0.71–1.03)</td>
</tr>
<tr>
<td>All participants</td>
<td>454/2104 (21.6%)</td>
<td>1065/4321 (24.6%)</td>
<td>0.83 (0.74–0.92)</td>
</tr>
</tbody>
</table>

RR=age−adjusted (or age−specific) rate ratio. CI=confidence interval. Subgroup−specific RR estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% confidence intervals.
**Figure S3: Effect of allocation to dexamethasone on: a) discharge from hospital within 28 days; and b) invasive mechanical ventilation or death, by level of respiratory support received at randomization**

### a) Discharge from hospital within 28 days

<table>
<thead>
<tr>
<th>Respiratory support at randomization</th>
<th>Dexamethasone</th>
<th>Usual care</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No oxygen received</td>
<td>366/501 (73.1%)</td>
<td>791/1034 (76.5%)</td>
<td>0.99 (0.87−1.12)</td>
</tr>
<tr>
<td>Oxygen only</td>
<td>887/1279 (69.4%)</td>
<td>1693/2604 (65.0%)</td>
<td>1.16 (1.07−1.26)</td>
</tr>
<tr>
<td>Invasive mechanical ventilation</td>
<td>107/324 (33.0%)</td>
<td>155/683 (22.7%)</td>
<td>1.51 (1.18−1.93)</td>
</tr>
<tr>
<td>All participants</td>
<td>1360/2104 (64.6%)</td>
<td>2639/4321 (61.1%)</td>
<td>1.11 (1.04−1.19)</td>
</tr>
</tbody>
</table>

Trend across three categories: $\chi^2_{1} = 9.84; \ p=0.002$

### b) Invasive mechanical ventilation or death (among those not on invasive mechanical ventilation at randomization)

<table>
<thead>
<tr>
<th>Respiratory support at randomization</th>
<th>Dexamethasone</th>
<th>Usual care</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No oxygen received</td>
<td>92/501 (18.4%)</td>
<td>150/1034 (14.5%)</td>
<td>1.20 (0.95−1.52)</td>
</tr>
<tr>
<td>Oxygen only</td>
<td>333/1279 (26.0%)</td>
<td>789/2604 (30.3%)</td>
<td>0.85 (0.77−0.95)</td>
</tr>
<tr>
<td>Subtotal</td>
<td>425/1780 (23.9%)</td>
<td>939/3638 (25.8%)</td>
<td>0.91 (0.82−1.00)</td>
</tr>
</tbody>
</table>

Trend across two categories: $\chi^2_{1} = 6.99; \ p=0.008$

RR=age−adjusted rate ratio for panel A and risk ratio for panel B. CI=confidence interval. Subgroup−specific RR estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% confidence intervals. The 'oxygen only' group includes non−invasive ventilation.